BAYERI1 Stock Overview
Engages in the pharmaceuticals, consumer health, and crop science businesses in Peru.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bayer S.A. (Peru) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S/20.00 |
| 52 Week High | S/20.10 |
| 52 Week Low | S/14.50 |
| Beta | 0.10 |
| 11 Month Change | 0% |
| 3 Month Change | 5.26% |
| 1 Year Change | 41.84% |
| 33 Year Change | 41.84% |
| 5 Year Change | 42.86% |
| Change since IPO | 315.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAYERI1 | PE Pharmaceuticals | PE Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -0.2% |
| 1Y | 41.8% | -26.6% | 13.5% |
Return vs Industry: BAYERI1 exceeded the PE Pharmaceuticals industry which returned -26.6% over the past year.
Return vs Market: BAYERI1 exceeded the PE Market which returned 13.5% over the past year.
Price Volatility
| BAYERI1 volatility | |
|---|---|
| BAYERI1 Average Weekly Movement | 2.2% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in PE Market | 10.0% |
| 10% least volatile stocks in PE Market | 1.0% |
Stable Share Price: BAYERI1 has not had significant price volatility in the past 3 months.
Volatility Over Time: BAYERI1's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | n/a | Heiko Klaus Mussmann | www.bayer.com/es/co/andina-y-cac-home |
Bayer S.A. (Peru) engages in the pharmaceuticals, consumer health, and crop science businesses in Peru. It operates through three segments: Crop Science, Pharmaceuticals, and Consumer Health. The company offers chemical crop protection products to control weeds; seeds and traits for corn, cotton, soybeans, oilseed rape/canola, rice, wheat, and other crops; biological and chemical products to protect crop plants against fungal diseases; biological and chemical products to protect crop plants from harmful insects and their larvae; vegetable seeds; digital applications for agriculture; products for consumer lawn and garden use and forestry, golf courses, railway tracks and landscape applications; biological and chemical seed treatment products to protect against fungal diseases and pests.
Bayer S.A. (Peru) Fundamentals Summary
| BAYERI1 fundamental statistics | |
|---|---|
| Market cap | S/294.47m |
| Earnings (TTM) | S/11.79m |
| Revenue (TTM) | S/319.14m |
25.0x
P/E Ratio0.9x
P/S RatioIs BAYERI1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYERI1 income statement (TTM) | |
|---|---|
| Revenue | S/319.14m |
| Cost of Revenue | S/224.05m |
| Gross Profit | S/95.09m |
| Other Expenses | S/83.30m |
| Earnings | S/11.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.80 |
| Gross Margin | 29.79% |
| Net Profit Margin | 3.69% |
| Debt/Equity Ratio | 0% |
How did BAYERI1 perform over the long term?
See historical performance and comparison